Matthew Foy is an accomplished professional with a diverse background in biological sciences, drug discovery, and entrepreneurship. He holds a BSc and MSc in Biological Sciences with a specialization in Cell and Molecular Biology from the University of Oxford. Additionally, he has pursued further studies in Drug Discovery at UCL and completed Entrepreneurship & Strategy Executive Modules at London Business School. Matthew Foy is currently a Partner at SROne, with a rich history of leadership roles and engagements in various organizations across different sectors.

With an impressive track record, Matthew Foy has served as a Board Member at prominent companies such as Fore Biotherapeutics, Decibel Therapeutics, PULMOCIDE LIMITED, Atox Bio, and many others. His extensive experience also includes roles as an Investor at Asceneuron SA, a Consultant / Seed Investor at PRESS London, and involvement in fundraising initiatives for institutions like The Grange Festival and The Royal Ballet School. Matthew Foy's broad expertise spans sectors ranging from biotechnology to film finance, demonstrating his versatility and business acumen.